Publications

Detailed Information

Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function

Cited 10 time in Web of Science Cited 13 time in Scopus
Authors

Devriese, Lot A.; Witteveen, Petronella (Els) O.; Mergui-Roelvink, Marja; Smith, Deborah A.; Lewis, Lionel D.; Mendelson, David S.; Bang, Yung-Jue; Chung, Hyun Choel; Dar, Mohammed M.; Huitema, Alwin D. R.; Beijnen, Jos H.; Voest, Emile E.; Schellens, Jan H. M.

Issue Date
2015-08
Publisher
Blackwell Publishing Inc.
Citation
British Journal of Clinical Pharmacology, Vol.80 No.2, pp.253-266
Abstract
AimsThe aim of the study was to determine the effect of renal impairment and prior platinum-based chemotherapy on the toxicity and pharmacokinetics of oral topotecan and to identify recommended doses for patients with renal impairment or prior platinum-based (PB) chemotherapy. MethodsA multicentre phase I toxicity and pharmacokinetic study of oral topotecan was conducted in patients with advanced solid tumours. Patients were grouped by normal renal function with limited or prior PB chemotherapy or impaired renal function (mild [creatinine clearance (CLcr)=50-79 ml min(-1)], moderate [CLcr=30-49 ml min(-1)], severe [CLcr <30 ml min(-1)]). ResultsFifty-nine patients were evaluable. Topotecan lactone and total topotecan area under the concentration-time curve (AUC) was significantly increased in patients with moderate and severe renal impairment (109% and 174%, respectively, topotecan lactone and 148% and 298%, respectively, total topotecan). Asian patients (23 in total) had higher AUCs than non-Asian patients with the same degree of renal impairment. Thirteen dose-limiting toxicities (DLTs) were observed, which were mostly haematological. The maximum tolerated dose (MTD) was 2.3 mg m(-2) day(-1), given on days 1 to 5 in a 21 day cycle, for patients with prior PB chemotherapy or mild renal impairment, and 1.2 mg m(-2) day(-1) for patients with moderate renal impairment (suggested dose 1.9 mg m(-2) day(-1) for non-Asians). Due to incomplete enrolment of patients with severe renal impairment, the MTD was determined as 0.6 mg m(-2) day(-1) in this cohort. ConclusionsOral topotecan dose adjustments are not required in patients with prior PB chemotherapy or mildly impaired renal function, but reduced doses are required for patients with moderate or severe renal impairment.
ISSN
0306-5251
URI
https://hdl.handle.net/10371/173004
DOI
https://doi.org/10.1111/bcp.12606
Files in This Item:
There are no files associated with this item.
Appears in Collections:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share